Data from: Incidence of cancer-associated thromboembolism in Japanese gastric and colorectal cancer patients receiving chemotherapy: a single-institutional retrospective cohort analysis (Sapporo CAT study)

Objective: Few data regarding the incidence of cancer-associated
thromboembolism (TE) are available for Asian populations. We investigated
the incidence of TE (TEi) and its risk factors among gastric and
colorectal cancer (GCC) patients who received chemotherapy in a daily
practice setting. Design: A retrospective cohort study. Setting: A single
institutional study that used data from Sapporo City General Hospital,
Japan, on patients treated between January 2008 and May 2015.
Participants: Five hundred Japanese GCC patients who started chemotherapy
from January 2008 to May 2015. Primary and secondary outcome measures: TE
was diagnosed by reviewing all the reports of contrast-enhanced computed
tomography (CT) performed during the follow-up period. All types of
thrombosis detected by CT or additional imaging tests, such as venous TE,
arterial TE, and cerebral infarction, were defined as TE. Medical records
of all identified patients were reviewed and potential risk factors for TE
including clinicopathological backgrounds were collected. We defined the
following patients as ‘active cancer’; patients with unresectable advanced
GCC, cancer recurrence during or after completing adjuvant (Adj)
chemotherapy, and/or presence of other malignant tumours. Results: Of the
500 patients, 70 patients (14.0%) developed TE during the follow-up
period. TEi was 9.2% and 17.3% in gastric and colorectal cancer patients,
18.1% and 3.5% in active and non-active cancer patients, and 24.0% and
12.9% in multiple and single primary, respectively. Multivariate logistic
regression analysis showed that colorectal cancer (odds ratio [OR], 2.371;
95% confidence interval [CI], 1.328 to 4.233), active cancer (OR 7.593;
95% CI 2.950 to 19.543), and multiple primary (OR 2.527; 95% CI 1.189 to
5.370) were independently associated with TEi. Conclusion: TEi was 14.0%
among Japanese GCC patients received chemotherapy, and was significantly
higher among patients with colorectal cancer, active cancer, and multiple
primary than among those with gastric cancer, non-active cancer, and
single primary, respectively.